Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5989)	3/21/2002 4:27:33 PM
From: SnowShredder	Respond to of 52153

Hi Peter & DAK, fwiw...I was talking to my former PI the other day about ES, He was thinking that ES could be used in conjunction with current therapies & in preventing metastisis . So if it is used to prevent metastisis, then it could potentially have to be used for the rest of their life(for ENMD would this be a bad thing? I don't think so ; ). If it works as a mono therapy it would probably be a slow tumor regression. The dosage probably has to optimized, as it took JF >2 years to optimize the dose for interferon alpha to treat angioblastomas, where @ first the docs thought that a high dose was the best, but the low dose was actually the best. Yesterday there was a couple of 97K blocks that went through ~8.30, and over 100 contracts of Jan 04 calls traded. (disclaimer, I'm long a BUNCH of calls for ASCO, hoping for some good CI data, so do your own DD)...BWDIK? Best of Luck, SS

To: Biomaven who wrote (5989)	3/21/2002 9:40:44 PM
From: LLCF	Respond to of 52153

Thanks.... I'll keep my eye on your eye! <VBG> DAK

To: Biomaven who wrote (5989)	3/31/2002 8:49:04 PM
From: aknahow	Respond to of 52153

Another area for anti-angiogenesis: Dr. Lloyd Paul Aiello, of Boston's Joslin Diabetes Center, reported data showing that administration of naturally occurring and synthetic derivatives of bactericidal/permeability-increasing protein (BPI), a human protein found in neutrophils that stops abnormal vascular growth in the retina, suppressed abnormal vascularization in mice by 40%. The investigators were also able to halt nearly 100% of the growth of vascular endothelial cells in culture using BPI derivatives. BPI administration also stimulated the growth of pericytes, which support small blood vessels in the eye. (Normally, pericytes only replicate every 20 years in the human body.) Pericytes are almost entirely lost in early diabetes, leading to retinopathy.